Price$5.83+0.18 (+3.27%)
01:30 PM07:45 PM
News · 26 weeks53-67%
2026-03-012026-08-23
Mix2790d
- Insider11(41%)
- SEC Filings10(37%)
- Other6(22%)
Latest news
25 items- SECSEC Form 10-Q filed by Cingulate Inc.10-Q - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessKANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. "While the regulatory process continues, our priorities remain clear: complete the remaining manufacturing work, submit a comprehensive response to the FDA, and continue preparing the organization for commercialization," said Cingulate Chairman and CEO Shane J. Schaffer. "We believe CTx-1301 has the potential to address a significant unmet need in A
- PRCingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic ProfileKANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed Release™ (PTR™) drug delivery platform, today announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs. The open-access manuscript provides clinicians and researchers with pharmacokinetic data supporting CTx-1301 (dexmethylphenidate HCl), Cingulate's lead product candidate for the treatment of attention-deficit/hyperactivity disorder (ADHD). Available through open access, the manuscript expands Ci
- PRCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent PsychopharmacologyKANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Phase 3 clinical trial results for its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of attention-deficit/hyperactivity disorder (ADHD), have been published in the Journal of Child and Adolescent Psychopharmacology and are now available through open access. The peer-reviewed publication helps establish the efficacy and safety profile of CTx-1301 and reinforces the potential o
- SECCingulate Inc. filed SEC Form 8-K: Leadership Update8-K - Cingulate Inc. (0001862150) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Schaffer Shane J.4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Commercial Officer Downey Bryan Wade4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERSEC Form 4 filed by Director Lawrence Bryan Jay4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERSEC Form 4 filed by EVP and Chief Medical Officer Brams Matthew4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Callahan Jennifer L.4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERSEC Form 4 filed by Director Hargroves Thomas Jeffrey4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERSEC Form 4 filed by Director Werth Peter J.4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CSO Silva Raul R.4 - Cingulate Inc. (0001862150) (Issuer)
- SECSEC Form S-8 filed by Cingulate Inc.S-8 - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Cingulate Inc. (0001862150) (Filer)
- INSIDERSEC Form 4 filed by EVP and CSO Silva Raul R.4 - Cingulate Inc. (0001862150) (Issuer)
- SECCingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Inc. (NASDAQ: CING) Added to Russell 3000E®KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index. "Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate's continued evolution as a public company," said Cingulate CEO Shane J. Schaffer. "We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As we advan
- SECCingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301's formulation and method of use through December 2042, further
- INSIDERDirector Hargroves Thomas Jeffrey bought $490,271 worth of shares (97,276 units at $5.04) (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERNew insider Hargroves Thomas Jeffrey claimed ownership of 192 shares (SEC Form 3)3 - Cingulate Inc. (0001862150) (Issuer)
- SECCingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Receives Complete Response Letter from FDA for CTx-1301No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter for its New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate HCl) for the treatment of A
CING FAQ
6 questionsWhere does CING stock trade?
Cingulate Inc. (CING) is listed on NASDAQ.What sector and industry is CING in?
Cingulate Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cingulate Inc. go public?
Cingulate Inc. (CING) completed its IPO in 2021.What are analysts saying about CING?
Cingulate Inc. has had 4 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $1200.00 price target on 2025-01-10. Recent price targets range from $850.00 to $1200.00.What companies are similar to CING?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CING side-by-side with any of them on Quantisnow.How can I track CING on Quantisnow?
Quantisnow aggregates Cingulate Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CING to receive live email and push alerts on every new disclosure.